The Peripheral Stents industry trends over the past 18 months have been shaped by strategic partnerships and M&A activity, as companies seek to strengthen their foothold in high-growth regions. Notably, in 2023, Boston Scientific acquired a mid-sized innovator in drug-eluting stent technology, expanding its portfolio for complex peripheral artery disease cases. Concurrently, Abbott partnered with a European vascular research institute to co-develop AI-driven stent designs, leveraging machine learning for improved patient outcomes. Regulatory shifts, including the FDA’s 2023 update to clinical trial guidelines for peripheral devices, have pushed manufacturers to prioritize long-term safety data in product approvals. Meanwhile, product launches have surged, with Medtronic and Stryker introducing next-gen nitinol stents featuring enhanced flexibility for below-the-knee interventions—a response to rising demand for minimally invasive treatments. The market has also seen a funding boost, as venture capital firms injected $120 million into startups specializing in bioresorbable stents, signaling confidence in sustainable vascular solutions. As healthcare systems prioritize cost-effective, durable interventions, the industry is poised for innovation-driven growth, particularly in Asia-Pacific markets where urbanization and diabetes prevalence are fueling peripheral artery disease cases.
